Numinus Wellness (TSE:NUMI) has released an update.
Numinus Wellness Inc. has joined forces with Cybin to begin Phase 3 trials of CYB003 for Major Depressive Disorder, marking a major step forward in mental health treatment. The trials, which will start in mid-2024, follow promising Phase 2 results that showed a significant reduction in depression symptoms, leading to an FDA breakthrough therapy designation. This collaboration underscores Numinus’s commitment to advancing mental health care through innovative therapies.
For further insights into TSE:NUMI stock, check out TipRanks’ Stock Analysis page.
